vimarsana.com

Latest Breaking News On - Drug repurposing service providers market - Page 1 : vimarsana.com

The real world evidence (RWE) market is projected to be worth USD 4 5 billion by 2030, growing at a CAGR of 15%

Roots Analysis Real World Evidence - Stakeholder Need Analysis In modern healthcare, the applications of real world data-based insights are vast, ranging from drug discovery to supporting regulatory decision-making LONDON, UNITED KINGDOM, March 3, 2021 /EINPresswire.com/ Roots Analysis has announced the addition of “Pharmaceutical and Life Sciences Real World Evidence Market, (2nd Edition), 2021-2030” report to its list of offerings. The digitization of data and advances in information processing, have led to the development of a wide array of tools and analytical algorithms that can now be used to mine pharmaceutical big data. The insights generated from such studies are increasingly being used to drive important judgements concerning pharmacology and healthcare. Presently, big pharmaceutical companies are estimated to spend nearly USD 20 million on an annual basis, on the generation of real world evidence to support their respective product development programs.

The real world evidence (RWE) market is projected to be worth USD 4 5 billion by 2030, growing at a CAGR of 15%, claims Roots Analysis – Business

iCrowdNewswire   Mar 3, 2021  2:30 AM ET In modern healthcare, the applications of real world data-based insights are vast, ranging from drug discovery to supporting regulatory decision-making; in fact, the US FDA routinely uses real world evidence to monitor post market safety of drugs Roots Analysis has announced the addition of “Pharmaceutical and Life Sciences Real World Evidence Market, (2nd Edition), 2021-2030” report to its list of offerings. The digitization of data and advances in information processing, have led to the development of a wide array of tools and analytical algorithms that can now be used to mine pharmaceutical big data. The insights generated from such studies are increasingly being used to drive important judgements concerning pharmacology and healthcare. Presently, big pharmaceutical companies are estimated to spend nearly USD 20 million on an annual basis, on the generation of real world evidence to support their respective product development pr

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.